Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS: Ziltivekimab in Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 38
01
Overview
A Phase 3 trial of ziltivekimab in atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), systemic inflammation, sponsored by Novo Nordisk. Started Aug 2021; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)chronic kidney disease (CKD)systemic inflammation
Beyond the preview
Go deeper on NCT05021835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021835.